The prognosis of chronic active Epstein-Barr virus infection (CAEBV) is very poor. We describe a 24-yearold male with severe CAEBV who was treated with allogeneic peripheral blood stem cell transplantation (allo-PBSCT). On admission, EBER-1 in lymphocytes infiltrating the liver, EBV-DNA in peripheral blood mononuclear cells (PBMC) and monoclonal NK cell proliferation were confirmed. After unsuccessful chemotherapy, he received an allo-PBSCT from his HLA-identical sister. Although he died of pulmonary hemorrhage on day +19, EBV-DNA was undetectable by PCR in PBMC, and the post-mortem liver showed no EBER-1-positive lymphocytes. This experience suggests that EBV-positive lymphocytes in CAEBV may be eradicated by allo-PBSCT, thereby raising the possibility of a new treatment modality. Bone Marrow Transplantation (2000) 26, 805-808. Keywords: chronic active Epstein-Barr virus infection; allogeneic peripheral blood stem cell transplantation; myeloablative conditioning regimen; EBV-specific CTL Chronic active Epstein-Barr virus infection (CAEBV) is characterized by clinical manifestations such as fever, extensive lymphadenopathy and hepatosplenomegaly, and laboratory findings including pancytopenia, polyclonal gammopathy and extremely high antibody titers to EpsteinBarr viral capsid antigen (VCA) and early antigen.
Chronic active Epstein-Barr virus infection (CAEBV) is characterized by clinical manifestations such as fever, extensive lymphadenopathy and hepatosplenomegaly, and laboratory findings including pancytopenia, polyclonal gammopathy and extremely high antibody titers to EpsteinBarr viral capsid antigen (VCA) and early antigen. [1] [2] [3] The prognosis of CAEBV is very poor and most CAEBV patients die from multiple organ failure, infection, or hematological malignancy within a few years. 4 The exact pathogenesis of CAEBV has not been clarified, and an effective treatment has not been established. 5 One of the difficulties that hampers the design of a new treatment modality is that CAEBV is very rare, and there have been only a few case reports or clinical trials that suggest a choice of treatment. Here, we describe our clinical experience of a patient with severe CAEBV, who was treated with myeloablative conditioning therapy followed by allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from an HLAidentical sibling donor.
Case report
A 24-year-old Japanese male was admitted to our hospital because of a 2-year history of intermittent high fever, cervical lymphadenopathy, hepatosplenomegaly and papules on his trunk and extremities. Physical examination confirmed mild splenomegaly, some cervical lymph node swellings and some papules mainly on lower extremities. Laboratory findings on admission revealed moderate anemia, thrombocytosis, lymphocytosis with 38% large granular lymphocytes (LGL; CD2 − , CD3 − , CD4 − , CD16 + , CD19 − , and CD56 + ), and liver dysfunction including elevated levels of serum asparate aminotransferase (AST) (209 IU/l; normal, Ͻ32 IU/l), alanine aminotransferase (ALT) (326 IU/l; normal, Ͻ39 IU/l), LDH (936 IU/l; normal, Ͻ455 IU/l) and hepaplastin test (HPT) (61%; normal, 70-120%). Bone marrow aspiration showed no marked increase in LGL. EBV serology was as follows: anti-VCA IgG titer, 5120-fold; anti-VCA IgA titer, Ͻ10-fold; anti-early antigen IgG titer, 5120-fold, and anti-EBV nuclear antigen (EBNA) titer, 40-fold. Skin biopsy showed prominent infiltration by lymphocytes, which were positive for latent membrane protein-1 (LMP-1) in perivascular lesions. Liver biopsy showed portal inflammation with infiltration of lymphocytes positive for cytoplasmic CD3. In situ hybridization studies demonstrated the presence of EBV-RNA (EBER-1) in the nuclei of lymphocytes in the skin, peripheral blood mononuclear cells (PBMC) and bone marrow. Liver biopsy also showed inflammation consisting of lymphocytes positive for EBER-1 on admission (Figure 1a) . Monoclonality of EBV terminal repeat sequence was confirmed in mononuclear cells obtained from liver and peripheral blood. There was no rearrangement in the T cell receptor ␤ gene. Based on these findings, he was diagnosed as CAEBV with monoclonal proliferation of NK cells.
The clinical course is shown in Figure 2 . First, he was treated with two cycles of CHOP chemotherapy (cyclophosphamide, adriamycin, vincristine and prednisolone) with cyclosporin A, but no response Figure 2 Semiquantitative PCR of EBV-DNA. Patient DNA was extracted from the PBMC using a phenol-chloroform method, and serially diluted 10-fold. The PCR protocol for EBV is described elsewhere. 22 The formation of a PCR product was detected by gel electrophoresis followed by ethidium bromide staining of the gel. The detection limit (of the PCR protocol) was estimated to be 10 copies (for semi-quantitation of viral DNAs present, positive samples were diluted 10-fold until they became PCR negative). The amount of viral DNA was calculated using the copy number of the detection limit of the virus and the amount of total DNA in the highest dilution that gave a visible signal, and then expressed as the number of copies per pg total DNA. occurred. He then received three cycles of high-dose Ara-C (3 g/body daily i.v. for 6 days; total dose, 18 g/body), which brought only a transient improvement in clinical symptoms. No further conventional chemotherapy was undertaken since treatment toxicities without benefit were anticipated. Finally, the patient was treated with myeloablative conditioning followed by allo-PBSCT from his HLAidentical EBV-seropositive sister. For mobilization of peripheral blood stem cells (PBSCs), granulocyte colony-stimulating factor (G-CSF) was administered subcutaneously at a dose of 10 g/kg to the donor for 6 consecutive days, and PBSCs were collected by leukapheresis on 4, 5 and 6 days of G-CSF administration, as previously reported. 6 The patient received a conditioning regimen consisting of 12 Gy total body irradiation (TBI) and high-dose cyclophosphamide (60 mg/kg once daily i.v. for 2 days), followed by the infusion of PBSC containing 4.82 × 10 6
CD34
+ cells/kg. Standard-dose cyclosporin A and shortterm methotrexate were used for prophylaxis of graft-versus-host disease (GVHD). His post-transplant course was complicated by a high fever without a definite focus of infection on day +2, and by severe mucositis and progressive liver dysfunction on day +7. He died of pulmonary hemorrhage due to Pseudomonas aeruginosa infection on day +19. Peripheral blood showed no hematological recovery; the white blood cell count was 200 per l with 4% neutrophils and daily platelet transfusions were required. Analysis of chimerism by variable number tandem repeat (VNTR) polymorphisms revealed that most PBMC and 72% of bone marrow cells were of donor type. A postmortem liver biopsy was performed with consent of the family and an immunohistochemical study showed that EBER-1-positive lymphocytes were not detected in Glisson's sheath (Figure 1b ).
Materials and methods

Induction of EBV-specific CTL against patient EBVtransformed B blasts
Two million PBMC isolated by centrifugation on FicollPaque (Pharmacia, Uppsala, Sweden) from the patient and his HLA-identical sibling donor were incubated with 2 × 10 5 irradiated patient EBV-transformed B blasts in a 24-well tissue culture plate (Falcon, Lincolon Park, NJ, USA) containing 2 ml of RPMI-1640 (Gibco BRL, Grand Island, NY, USA) supplemented with 10% heat inactivated human AB serum, 0.1 mm MEM nonessential amino acid solution (Gibco BRL), 50 m 2-mercaptoethanol, 0.1 mm MEM sodium pyruvate solution (Gibco BRL), and 100 units/ml recombinant interleukin-2 (a gift from Takeda Pharmaceutical, Osaka, Japan) for 7 days at 37°C in a humidified atmosphere with 5% CO 2 in air. The cells were maintained as a bulk CTL line by weekly stimulation with irradiated patient EBV-transformed B blasts. After four stimulations, the CTL line-derived cells were used for a cytotoxicity assay.
Cell-mediated cytotoxicity assay
Patient EBV-transformed B blasts (1 × 10 6 ) were labeled by incubation with 2 MBq of 51 Cr for 1 h at 37°C with 5% CO 2 in air. The radiolabeled cells were then washed and used as target cells. In direct assays, 5 × 10 3 labeled target cells (100 l) were incubated with the effector cell suspension (100 l). After 4 h incubation, the supernatant (100 l) was removed and its radioactivity was measured with a gamma counter. The percentage of specific lysis was calculated by the following equation: [(A − B)/(C − B)] × 100, where A is the radioactivity in the supernatant of target cells mixed with effector cells, B is that in the supernatant of target cells incubated alone, and C is that in the supernatant after lysis of target cells with 1% NP-40. Figure 3 , CTL generated from PBMC of the sibling donor had cytotoxicity against the patient's EBVtransformed B blasts. In contrast, CTL generated from PBMC of the patient had no cytotoxicity. The cytotoxicity was confirmed at five different E/T ratios (40, 20, 10, 5, 2.5). Cytotoxicity assays were repeated at least twice in separate experiments, with consistent results.
Results
As shown in
Discussion
There is no standard treatment which is effective for CAEBV. [7] [8] [9] Lymphokines, anti-viral agents and anti-cancer agents have been sporadically reported to be effective, but no generally effective therapies for this progressive disease which are able to eradicate EBV from the host have been identified. [8] [9] [10] [11] In the present case, we monitored levels of EBV-DNA in PBMC as a marker of therapeutic effect (Figure 2 ). EBV-DNA was detectable after treatment with CHOP and high-dose Ara-C, while it was not detected by PCR after allo-PBSCT. Moreover, post-mortem showed none of the EBER-1-positive lymphocytes which had infiltrated the liver on admission. This observation suggests that myeloablative conditioning followed by allo-PBSCT might be successful in eradicating EBV-positive lymphocytes.
Although the pathogenesis of CAEBV remains unclear, impaired cellular immune responses to EBV rather than impaired virus-antigen presentation of the infected cells have been suggested as the cause. 3, 5, 12, 13 In the present case, we were able to generate anti-EBV-specific CTL from PBMC of the patient's HLA-matched sibling donor, but not from his own PBMC (Figure 3 ). This observation suggests a possible immunological effect provided by allogeneic transplantation from an HLA-identical donor whose immune response to EBV is normal. Successful use of allo-BMT or allo-PBSCT against aggressive cases of EBVrelated clonal diseases such as EBV-associated lymphoproliferative disorder 14, 15 and EBV-associated NK cell large granular lymphocytic leukemia 16, 17 have recently been reported. These clinical experiences suggest that this treatment strategy may be effective for other poor prognosis EBV-related disorders, including CAEBV.
One of the problems associated with allogeneic transplantation is the high incidence of transplant-related mortality. Unfortunately, the present patient died of pulmonary infection during the early post-transplant period. Recently, non-myeloablative preparative regimens have been introduced in allogeneic transplantation for patients with various hematological malignancies. 18 Less intensive conditioning regimens are tolerated in older patients or those with a poorer performance status. The curative potential of this strategy is considered to be mediated by immune-mediated T cell response. In EBV-associated post-transplant lymphoproliferative disorders, donor lymphocytes infusion and EBV-specific CTL infusions are reported to be effective. 19, 20 Less intensive conditioning coupled with allo-PBSCT may reduce treatment-related mortality and the subsequent donor lymphocyte infusions may result in suppression of EBV. However, it is not known whether cytotoxicity by EBV-specific CTLs derived from donor-derived T cells will cure CAEBV without myeloablation. Kuzushima et al 21 reported that adoptive transfer of anti-EBV CTL from an HLA-matched sibling to a patient with severe CAEBV transiently reduced the amount of EBV DNA, although this did not result in eradication of the EBVinfected cells. Cytotoxicity by CTL alone may be insufficient to eradicate EBV-infected cells. Since the present patient died before sustained engraftment, it is probable that the disappearance of EBV-DNA from PBMC was mediated by the myeloablative therapy rather than by cytotoxicity of EBV-specific CTLs, which would be functionally differentiated from donor-derived T cells. Further allo-PBSCTs in patients with CAEBV may clarify the cytotoxic and immunological effects in this situation.
